178 related articles for article (PubMed ID: 27209505)
1. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART).
Ringash J; Fisher R; Peters L; Trotti A; O'Sullivan B; Corry J; Kenny L; Nuyts S; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):678-686. PubMed ID: 27209505
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.
Hegde JV; Shaverdian N; Daly ME; Felix C; Wong DL; Rosove MH; Garst JH; Wang PC; Veruttipong D; Rao S; Fragoso RC; Riess JW; Steinberg ML; Chen AM
Cancer; 2018 Feb; 124(3):521-529. PubMed ID: 29044458
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.
Galloway TJ; Zhang QE; Nguyen-Tan PF; Rosenthal DI; Soulieres D; Fortin A; Silverman CL; Daly ME; Ridge JA; Hammond JA; Le QT
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):362-371. PubMed ID: 27478170
[TBL] [Abstract][Full Text] [Related]
7. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
8. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
9. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
Sapir E; Tao Y; Feng F; Samuels S; El Naqa I; Murdoch-Kinch CA; Feng M; Schipper M; Eisbruch A
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):354-361. PubMed ID: 27473816
[TBL] [Abstract][Full Text] [Related]
12. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.
Deschuymer S; Sørensen BS; Dok R; Laenen A; Hauben E; Overgaard J; Nuyts S
Strahlenther Onkol; 2020 Jun; 196(6):552-560. PubMed ID: 32080773
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors.
Slavik M; Kazda T; Selingerová I; Šána J; Ahmad P; Gurín D; Hermanová M; Novotný T; Červená R; Dymáčková R; Burkoň P; Slabý O; Šlampa P
Klin Onkol; 2019; 32(1):58-65. PubMed ID: 30764631
[TBL] [Abstract][Full Text] [Related]
15. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
16. Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status.
Kim MJ; Ki MS; Kim K; Shim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Lee JK; Yoon TM; Lim SC; Chung WK; Jeong JU; Lim HS; Choi YD; Cho SH
BMC Cancer; 2014 Nov; 14():824. PubMed ID: 25380690
[TBL] [Abstract][Full Text] [Related]
17. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.
Pearlstein KA; Wang K; Amdur RJ; Shen CJ; Dagan R; Weiss J; Grilley-Olson JE; Zanation A; Hackman TG; Thorp BD; Blumberg JM; Patel S; Sheets N; Weissler MC; Mendenhall WM; Chera BS
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):646-653. PubMed ID: 30395903
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
20. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
